Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jul;20(3):426-39, table of contents.
doi: 10.1128/CMR.00009-07.

Molecular testing in the diagnosis and management of chronic hepatitis B

Alexandra Valsamakis  1
Affiliations
Review

Molecular testing in the diagnosis and management of chronic hepatitis B

Alexandra Valsamakis. Clin Microbiol Rev. 2007 Jul.

Abstract

Hepatitis B virus (HBV) is an enveloped virus with a small (3.2-kb) partially double-stranded DNA genome that causes acute and chronic infections. The impact of these infections on public health worldwide is enormous, with an estimated prevalence of 2 billion acute infections and 360 million chronic infections globally. This review focuses on chronic hepatitis B and the molecular assays used in its diagnosis and management. Background information, including that about features of the hepatitis B virion, viral replication, and epidemiology of infection, that is important for understanding chronic hepatitis B and molecular diagnostic tests for HBV is provided. To facilitate an understanding of the utility of molecular testing for chronic hepatitis B, the four stages of chronic hepatitis B infection that are currently recognized, as well as an additional entity, occult hepatitis B, that can be diagnosed only by sensitive nucleic acid amplification methods, are reviewed in detail, including available therapeutic agents. The molecular diagnostic content focuses on tests for HBV DNA quantification, genotyping, and mutation detection (including precore/core promoter and antiviral resistance mutations). The discussion of these tests encompasses their current utility and performance characteristics, drawing from current clinical guidelines and other studies from the literature. In recognition of the continual evolution of this field, the final section describes emerging molecular markers with future diagnostic potential.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Geographic distribution of HBV genotypes. Letter sizes indicate relative prevalences in regions with multiple genotypes. Lowercase letters indicate HBV subtypes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aberle, S. W., J. Kletzmayr, B. Watschinger, B. Schmied, N. Vetter, and E. Puchhammer-Stockl. 2001. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J. Clin. Microbiol. 39:1972-1974. - PMC - PubMed
    1. Ahn, S. H., Y. N. Park, J. Y. Park, H. Y. Chang, J. M. Lee, J. E. Shin, K. H. Han, C. Park, Y. M. Moon, and C. Y. Chon. 2005. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J. Hepatol. 42:188-194. - PubMed
    1. Akuta, N., F. Suzuki, M. Kobayashi, A. Tsubota, Y. Suzuki, T. Hosaka, T. Someya, M. Kobayashi, S. Saitoh, Y. Arase, K. Ikeda, and H. Kumada. 2003. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J. Hepatol. 38:315-321. - PubMed
    1. Alberti, A. 2003. Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B? Hepatology 38:18-20. - PubMed
    1. Allain, J. P. 2004. Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 86:83-91. - PubMed

Publication types

MeSH terms

LinkOut - more resources